Champions Oncology (CSBR) Income from Continuing Operations (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Income from Continuing Operations of 667000.0 for Q2 2026, up 63.65% year-over-year from 407574.09 in Q2 2025, and down 139.07% quarter-over-quarter from 279000.0 in Q1 2026.
Champions Oncology (CSBR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Champions Oncology's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 667000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 63.65% year-over-year to 667000.0; the TTM figure through Apr 2026 stood at 1175000.0 (down 124.99% YoY), while the FY2026 annual figure was 1175000.0, down 124.99% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 667000.0, down from 279000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4495000.0 in Q1 2025, with the low at 2566000.0 in Q3 2023.
- The 5-year median for Income from Continuing Operations is 331500.0 (2022), against an average of 480111.11.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 12843.75% in 2023, then soared 277.67% in 2025.
- Champions Oncology's Income from Continuing Operations stood at 16000.0 in 2022, then plunged by 12843.75% to 2071000.0 in 2023, then surged by 135.15% to 728000.0 in 2024, then slumped by 67.45% to 237000.0 in 2025, then slumped by 381.43% to 667000.0 in 2026.
- Business Quant data shows CSBR's Income from Continuing Operations at 667000.0 in Q2 2026, 279000.0 in Q1 2026, and 237000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | -667,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -667,000.00 |
| Jan 31, 2026 | -279,000.00 |
| Oct 31, 2025 | 237,000.00 |
| Jul 31, 2025 | -466,000.00 |
| Apr 30, 2025 | -1.84 Mn |
| Jan 31, 2025 | 4.50 Mn |
| Oct 31, 2024 | 728,000.00 |
| Jul 31, 2024 | 1.31 Mn |
| Apr 30, 2024 | -109,000.00 |
| Jan 31, 2024 | -2.53 Mn |
| Oct 31, 2023 | -2.07 Mn |
| Jul 31, 2023 | -2.57 Mn |
| Apr 30, 2023 | -2.56 Mn |
| Jan 31, 2023 | -2.44 Mn |
| Oct 31, 2022 | -16,000.00 |
| Jul 31, 2022 | -319,000.00 |
| Apr 30, 2022 | -344,000.00 |
| Jan 31, 2022 | 787,000.00 |
| Oct 31, 2021 | 277,000.00 |
| Jul 31, 2021 | -172,000.00 |